Several innovative products by Luye Pharma Group (HKG:2186) have been included in the National Reimbursement Drug List for basic medical insurance, work-related injury insurance, and maternity insurance, a Thursday bourse filing said.
Antidepressant Ruoxinlin has been included in the list for the time, cancer drug Baituowei has made it for a new indication for breast cancer, and tumor drug Lipusu is included in the regular catalogue of the list.
The list will officially take effect on Jan. 1, 2025.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。